A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot

Ryan Cross

Senior Science Correspondent

Two nonprofit organizations are teaming up for a giant study of an experimental vaccine designed to protect against the world’s deadliest infectious disease.

The Bill …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Chinese drugmaker receives FDA warning letter after management hindered inspection

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

FDA rejects Astellas’ effort to support longer use of eye drug Izervay

Are programs with compounded GLP-1s safe for your population?

A cen­tu­ry af­ter the last ma­jor TB vac­cine break­through, Gates and Well­come com­mit $550M for PhI­II test of GSK shot

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot

Chinese drugmaker receives FDA warning letter after management hindered inspection

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

FDA rejects Astellas’ effort to support longer use of eye drug Izervay

Are programs with compounded GLP-1s safe for your population?